This poster was developed and funded by MSD. This poster contains promotional information and is intended for UK healthcare professionals only.
Prescribing and adverse event reporting information can be found at the bottom of this poster.

KEYTRUDA SC®
(pembrolizumab)
subcutaneous injection
395 mg/2.4 mL
790 mg/4.8 mL

Dosing, storage, and preparation of KEYTRUDA SC® for subcutaneous injection

Dosing schedules

Two dosing options and solution-strength vials are available for KEYTRUDA SC:[1,2]

Dose: Q3W

Administered subcutaneously over **1 minute***

Low injection volume: **2.4 mL**

395 mg pembrolizumab

Yellow cap



OR

Dose: Q6W

Administered subcutaneously over **2 minutes***

Low injection volume: **4.8 mL**

790 mg pembrolizumab

Green cap



Vials shown to scale, not actual size.

Dosing video

Click here to watch the **Dosing, Preparation, and Administration video**



This link will direct you to an MSD promotional website

Storage

Storage of unopened vials:[1,2]

KEYTRUDA SC has the same storage requirements as KEYTRUDA IV[1,2,3]

- Store in a refrigerator (2°C–8°C)
- Store in the original carton to protect from light
- Do not shake or freeze vials

If **removed** from refrigeration, unpunctured vials can remain at room temperature (≤25°C) for up to 24 hours before preparation for administration.

Storage of the prepared syringes:[1,2]

This product does not contain preservative and **should be used immediately after withdrawing from the vial**. If not used immediately, store the syringe containing KEYTRUDA SC with the **transfer needle and cap in place for:****

Up to 8 hours at room temperature

OR

Up to 24 hours in the refrigerator (2°C–8°C)

The 24-hour period may include up to 8 hours at room temperature.

If refrigerated, the filled syringe must be allowed to come to room temperature for at least 30 minutes prior to administration.

The syringe must not be frozen.

Do not attach the hypodermic needle until immediately prior to administration to avoid clogging.

Discard if storage time exceeds these limits

- Do not store any unused portion of the solution for the injection for reuse
- Any unused medicine or waste material should be disposed of in accordance with local requirements

Preparation

How to prepare the KEYTRUDA SC syringe for injection:[1,2]

1 Check the vial

Check the vial label to ensure the correct formulation is prepared and administered to the patient as prescribed.

Visually inspect the vial for particulate matter and discolouration.
The solution is clear to slightly opalescent, colourless to slightly yellow.

Discard the vial if visible particles or discolouration are observed.




2 Bring the vial to room temperature

Allow the refrigerated vial to come to room temperature for at least 30 minutes.

Prior to the preparation for administration, if needed, the **unpunctured vial may be stored at room temperature for up to 24 hours.**

Do not dilute, do not shake the vial.




3 Withdraw the required volume

Withdraw either 2.4 mL (395 mg) or 4.8 mL (790 mg) using a sterile syringe and a **transfer needle (18–21G recommended)**.

KEYTRUDA SC is compatible with polypropylene and polycarbonate syringe material and stainless-steel transfer and injection needles.

KEYTRUDA SC vial is for single use only. Discard the empty vial or any unused portion left in the vial.†



4 Change to injection needle before use

To avoid needle clogging, change the needle to a 25–30G, 13 mm hypodermic injection needle immediately prior to subcutaneous injection.

Do not attach the hypodermic needle until immediately prior to administration to avoid clogging.



Preparation should be performed by trained personnel in accordance with your local hospital guidance and with good practice (e.g. aseptic technique)

Administration


KEYTRUDA SC is administered over 1 or 2 minutes, with two subcutaneous injection-site options: the abdomen or thigh[1,2]

Should be administered by an HCP and must be administered by subcutaneous injection only:

Q3W — Inject over **1 minute*** one dose (395 mg/2.4 mL)

OR

Q6W — Inject over **2 minutes*** one dose (790 mg/4.8 mL)



Administration techniques

- Inject into the subcutaneous tissue of the **thigh or abdomen**, avoiding the 5 cm area around the navel
- Do not inject into skin that is damaged, sore, bruised, scarred, scaly, or has red patches
- **Rotate injection sites** for subsequent injections (ensure the injection site is at least 2.5 cm from the previous injection site)
- During treatment with KEYTRUDA SC do not administer other medicinal products for subcutaneous use at the same site
- To best prepare for injection, consider recommending that your patients wear loose-fitting clothes, such as a skirt or shorts

Disposal

- Vials are for single use only and any unused portion should be discarded
- Dispose in accordance with local requirements

Prescribing Information

KEYTRUDA SC is licensed for use across most KEYTRUDA IV indications, whether alone or in combination with other therapies.[1-3]

One such indication: KEYTRUDA IV and SC, in combination with pemetrexed and platinum chemotherapy, are each indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no *EGFR* or *ALK* positive mutations.[1-3]

Please consult the SmPC and risk minimisation materials for further information before making prescribing decisions.

Click on the boxes below for UK prescribing information.
These links will direct you to a third party website:‡

KEYTRUDA SC 395 mg/2.4 mL	KEYTRUDA SC 790 mg/4.8 mL	KEYTRUDA IV

The approved adult indications for KEYTRUDA SC have been established based on the MK-3475A-D77 study, which demonstrated non-inferior pharmacokinetics, and provides a descriptive analysis for the efficacy and safety profile of KEYTRUDA SC compared to KEYTRUDA.[1,2]

The safety and efficacy of KEYTRUDA SC have not been established in paediatric patients, except for adolescents with melanoma or cHL aged 12 years and older who weigh more than 40 kg. For these adolescents, the recommended dose is the same as that for adults. The paediatric safety and efficacy profile of KEYTRUDA SC is based on extrapolation from intravenous pembrolizumab studies, as efficacy and safety in paediatric patients were not directly evaluated in the MK-3475A-D77 study.[1,2]

In addition, pharmacokinetic modelling and simulation analyses demonstrated similar pembrolizumab exposure in adolescents aged 12 years and older who weigh more than 40 kg compared with adults, suggesting a similar safety profile. Pembrolizumab exposures with subcutaneous doses of 395 mg every 3 weeks or 790 mg every 6 weeks in adolescents aged 12 years and older who weigh greater than 40 kg are expected to be an average of 30% higher to those of adult patients at the same dose, however this difference is not clinically meaningful.[1,2]

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 020 8154 8000). This link will direct you to a third party website.‡

*Does not account for all aspects of treatment. Actual clinic time may vary; **In-use storage times and conditions prior to use are the responsibility of the user; † Any unused medicinal product or waste material should be disposed of in accordance with local requirements; ‡ MSD makes no warranties or representations of any kind as to the accuracy, completeness, reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information. Inclusion of any third-party link does not imply an endorsement or recommendation by MSD.
ALK, anaplastic lymphoma kinase; cHL, classical Hodgkin lymphoma; *EGFR*, epidermal growth factor receptor; G, gauge; HCP, healthcare professional; IV, intravenous; MHRA, Medicines and Healthcare products Regulatory Agency; Q3W, every 3 weeks; Q6W, every 6 weeks; SC, subcutaneous; SmPC, Summary of Product Characteristics.
1. KEYTRUDA (pembrolizumab) 395 mg Solution for Injection Summary of Product Characteristics; **2.** KEYTRUDA (pembrolizumab) 790 mg Solution for Injection Summary of Product Characteristics; **3.** KEYTRUDA (pembrolizumab) 25 mg/mL Concentrate Solution for Infusion Summary of Product Characteristics.

GB-PDS-00119 | October 2026

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Merck Sharp & Dohme (UK) Limited.
Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 00233687.

MSD